These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Plasma exchange therapy (plasmapheresis/plasmafiltration). II. Indications and complications]. Quietzsch D; Liebert A; Zimmermann S Z Gesamte Inn Med; 1984 Oct; 39(20):493-500. PubMed ID: 6549091 [TBL] [Abstract][Full Text] [Related]
25. [Favorable results of plasmapheresis in severe myasthenia gravis]. Blom RJ; Kuks JB; Westerterp-Maas A; Oosterhuis HJ Ned Tijdschr Geneeskd; 1997 Feb; 141(8):381-4. PubMed ID: 9157298 [TBL] [Abstract][Full Text] [Related]
26. [Plasmapheresis in the treatment of immunological nephropathies]. Frasca' G; Vangelista A; Nanni Costa A; Cucudis P G Clin Med; 1981 Apr; 62(4):260-9. PubMed ID: 7021294 [No Abstract] [Full Text] [Related]
27. [Effects of plasmapheresis on neuromuscular transmission in myasthenia gravis]. De Léan J Union Med Can; 1983 Jan; 112(1):9-13. PubMed ID: 6301126 [No Abstract] [Full Text] [Related]
28. Therapeutic apheresis. Applications and future directions. Kennedy MS; Domen RE Vox Sang; 1983; 45(4):261-77. PubMed ID: 6356587 [TBL] [Abstract][Full Text] [Related]
29. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital. Pittayanon R; Treeprasertsuk S; Phanthumchinda K J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297 [TBL] [Abstract][Full Text] [Related]
31. Plasmapheresis does not affect polysomnographic parameters in patients with myasthenia gravis: a case series study. Yeh JH; Chen WH; Chiu HC; Lee CT; Hsu CY Artif Organs; 2010 Jun; 34(6):E200-3. PubMed ID: 20456321 [TBL] [Abstract][Full Text] [Related]
33. Myasthenia gravis: treatment with plasma exchange experiences over 10 years. Fornádi L; Horváth R; Szobor A Acta Med Hung; 1991; 48(3-4):137-44. PubMed ID: 1822852 [TBL] [Abstract][Full Text] [Related]
34. [Plasmapheresis in the treatment of myasthenia gravis]. Yusta A; Jiménez MD; Liaño H Rev Clin Esp; 1986 Jun; 179(2):65-8. PubMed ID: 3738062 [No Abstract] [Full Text] [Related]
35. Plasmapheresis. Therapeutic or experimental procedure? Dau PC Arch Neurol; 1984 Jun; 41(6):647-53. PubMed ID: 6202282 [No Abstract] [Full Text] [Related]
37. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Mandawat A; Mandawat A; Kaminski HJ; Shaker ZA; Alawi AA; Alshekhlee A Muscle Nerve; 2011 Apr; 43(4):578-84. PubMed ID: 21404289 [TBL] [Abstract][Full Text] [Related]
38. [Pinpointing neuro-immunologic diseases]. Steck AJ Schweiz Med Wochenschr; 1984 Oct; 114(43):1478-83. PubMed ID: 6083604 [TBL] [Abstract][Full Text] [Related]
39. Plasma exchange in myasthenia gravis: electrophysiological studies. Campbell WW; Leshner RT; Swift TR Ann Neurol; 1980 Dec; 8(6):584-9. PubMed ID: 6260011 [TBL] [Abstract][Full Text] [Related]
40. [Analysis of prognostic factors and efficacy of plasmapheresis in the treatment of myasthenia crisis]. Feng HY; Liu WB; Qiu L; He XT; Zhang Y; Huang X; Huang RX Zhonghua Yi Xue Za Zhi; 2010 Dec; 90(47):3343-6. PubMed ID: 21223750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]